1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Glaukos Acquires Avedro

M&A Deal Summary

Glaukos Acquires Avedro

On August 7, 2019, Glaukos acquired medical products company Avedro

Acquisition Highlights
  • This is Glaukos’ 2nd transaction in the Medical Products sector.
  • This is Glaukos’ 2nd transaction in the United States.
  • This is Glaukos’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2019-08-07
Target Avedro
Sector Medical Products
Buyer(s) Glaukos
Deal Type Add-on Acquisition
Advisor(s) Guggenheim Securities (Financial)
Cooley (Legal)

Target

Avedro

Waltham, Massachusetts, United States
Avedro, Inc. is a hybrid ophthalmic pharmaceutical and medical technology company focused on treating corneal disease and disorders and improving vision to reduce dependency on eyeglasses or contact lens. Avedro’s proprietary bio-activated pharmaceuticals strengthen, stabilize, and reshape the cornea to treat corneal ectatic disorders and correct refractive conditions. Avedro, Inc. was founded in 2002 and is headquartered in Waltham, Massachusetts.

Search 215,074 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Glaukos

Aliso Viejo, California, United States
Category Company
Founded 1998
Sector Medical Products
Employees995
Revenue 383M USD (2024)
DESCRIPTION

Glaukos is a medical device company focused on developing ophthalmic stents for minimally invasive treatment of patients with glaucoma. Glaukos was founded in 1998 and is based in Aliso Viejo, California.

DEAL STATS #
Overall 2 of 2
Sector: Medical Products M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
State: Massachusetts M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2019 M&A 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-06-19 DOSE Medical

Los Angeles, California, United States

DOSE Medical Corp. is a developer of multiple micro-invasive, bioerodible, sustained-release drug delivery platforms designed to be used in the treatment of various retinal diseases, including age-related macular degeneration (AMD) and diabetic macular edema.

Buy $3M
Mergr

Solution for

Product

Company

Legal